We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

131 hedge funds and large institutions have $524M invested in Amylyx Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 37 increasing their positions, 37 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,338% more call options, than puts

Call options by funds: $1.48M | Put options by funds: $103K

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

100% more capital invested

Capital invested by funds: $262M → $524M (+$262M)

8.24% more ownership

Funds ownership: 83.41% → 91.64% (+8.2%)

0% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 37

4% less funds holding

Funds holding: 136 → 131 (-5)

14% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 36

Holders
131
Holders Change
-5
Holders Change %
-3.68%
% of All Funds
1.72%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.08%
New
31
Increased
37
Reduced
37
Closed
36
Calls
$1.48M
Puts
$103K
Net Calls
+$1.38M
Net Calls Change
+$1.46M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$17.6M
2
BlackRock
BlackRock
New York
+$15.2M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$15.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.19M
5
DCM
Driehaus Capital Management
Illinois
+$6.15M

Top Sellers

Rank Fund Capital Flow
1
Aberdeen Group
Aberdeen Group
United Kingdom
-$8.23M
2
Millennium Management
Millennium Management
New York
-$7.64M
3
Citadel Advisors
Citadel Advisors
Florida
-$7.37M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6.62M
5
Goldman Sachs
Goldman Sachs
New York
-$3.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHS
26
PFM Health Sciences
California
$4.69M -$496K -101,879 -12%
PHP
27
Parkman Healthcare Partners
Connecticut
$4.17M +$3.16M +650,000 New
SSA
28
Schonfeld Strategic Advisors
New York
$4.14M +$2.57M +529,303 +452%
Deutsche Bank
29
Deutsche Bank
Germany
$3.95M +$224K +46,062 +8%
Charles Schwab
30
Charles Schwab
California
$3.77M +$1.05M +215,558 +58%
Invesco
31
Invesco
Georgia
$3.76M +$2.63M +541,189 +1,184%
Acadian Asset Management
32
Acadian Asset Management
Massachusetts
$3.65M +$1.59M +326,976 +135%
Two Sigma Investments
33
Two Sigma Investments
New York
$3.58M -$988K -203,207 -27%
RSCM
34
Rock Springs Capital Management
Maryland
$3.2M +$761K +156,536 +46%
Morgan Stanley
35
Morgan Stanley
New York
$3.12M +$60.7K +12,475 +3%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$3.01M -$875K -179,800 -28%
Bank of America
37
Bank of America
North Carolina
$2.9M -$1.67M -342,546 -43%
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$2.81M -$2.46M -504,865 -54%
Renaissance Technologies
39
Renaissance Technologies
New York
$2.54M -$578K -118,900 -23%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$2.4M +$1.22M +250,163 +202%
O
41
OrbiMed
New York
$2.01M -$169K -34,800 -10%
Wellington Management Group
42
Wellington Management Group
Massachusetts
$1.85M -$10K -2,064 -0.7%
AWG
43
Alpha Wave Global
New York
$1.77M +$431K +88,531 +47%
JGC
44
J. Goldman & Co
New York
$1.66M +$1.26M +258,600 New
YIH
45
Y-Intercept (HK)
Hong Kong
$1.54M +$1.17M +240,379 New
TAM
46
TFG Asset Management
Cayman Islands
$1.4M +$1.06M +218,750 New
AC
47
Aldebaran Capital
Indiana
$1.4M -$201K -41,426 -16%
Federated Hermes
48
Federated Hermes
Pennsylvania
$1.31M +$5.57K +1,145 +0.6%
Jane Street
49
Jane Street
New York
$1.2M -$701K -144,199 -44%
GCP
50
GSA Capital Partners
United Kingdom
$1.09M +$717K +147,448 +639%
1
2
3 4 5

AMLX Hedge Fund Activity: Q2 2025 in Review

131 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2025, worth a combined $524M — up 100% from $262M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 31 opened new positions — a net loss of 5 holders — while 37 trimmed existing stakes and 37 added.

The largest buyer was Point72 Asset Management, adding an estimated $17.6M. The largest seller was Aberdeen Group, cutting an estimated $8.23M.

  • 131 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2025, down from 136 in Q1 2025.
  • Funds reported $524M of Amylyx Pharmaceuticals stock for Q2 2025, up 100% quarter-over-quarter.
  • 31 funds opened new Amylyx Pharmaceuticals positions in Q2 2025 and 36 closed out, a net change of -5 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $17.6M added.
  • The largest Amylyx Pharmaceuticals seller in Q2 2025 was Aberdeen Group, an estimated $8.23M sold.

Based on aggregated 13F filings for Q2 2025.